November 21, 2018 — BTG plc announced the first Ekos CU 4.0 units have been shipped from BTG’s facility in Bothell, Wash., to Europe, where full commercial launch will begin. New features of the Ekos CU 4.0 include an interactive colour touchscreen, a built-in battery and separate ports for managing two Ekos devices simultaneously.
These improvements simplify bilateral treatment of pulmonary embolism (PE) and deep vein thrombosis (DVT). Using CU 4.0, physicians can treat both pulmonary arteries and can easily monitor and manage two Ekos devices at the same time.
European patients with PEs and DVTs have already successfully been treated with Ekos CU 4.0 during a limited release of the product.
Prof. Nils Kucher, director of clinic of angiology at University Hospital in Zurich, Switzerland said: “I’ve used Ekos therapy for over 10 years. This latest innovation of the technology is a big step for simplifying thrombosis treatment.”
Ekos is the only device to have both U.S. Food and Drug Administration (FDA) clearance and a CE Mark for the treatment of PE. The system includes an ultrasonic device that uses acoustic pulses, which enable quick and safe dissolution of blood clots and restore blood flow in patients with PE, DVT and peripheral arterial occlusions.
For more information: www.btgplc.com
March 20, 2026 
